Articles from Centauri Therapeutics Limited

Centauri Therapeutics Limited (Centauri), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, today announced the selection of its first clinical candidate in the ABX-01 programme. Based on the Company’s Alphamer® platform, the compound is designed to target serious Gram-negative bacterial infections in the lung, expanding therapeutic options for the most vulnerable patients. This drug candidate will now be further developed ahead of progression to first in-human clinical studies.

Centauri Therapeutics Limited (Centauri), an immunotherapy company focused on the treatment of infectious diseases, today announced three senior appointments: Dr Jennifer Schneider as Chief Executive Officer (CEO), Dr Helen Bright as Vice President (VP) of Research & Development (R&D), and Professor David Roblin FRCP FMedSci as Chair of the Board of Directors. The appointments bring extensive expertise in the discovery, development and commercialisation of medicines to treat infectious diseases, and further support the development of Centauri’s pipeline of novel candidates, built on the Alphamer® platform, through to first-in-human trials.

Centauri Therapeutics Limited (Centauri), an immunotherapy company founded by Animatrix Founders LLP and focused on the treatment of infectious diseases, today announced the close of its £24 million GBP (c. 32 million USD) Series A investment round. The funds will support the continued advancement of the Company’s antimicrobial resistance (AMR) research and development, using the Alphamer® platform to identify and progress novel antibacterial candidates through first-in-human trials, for difficult-to-treat infections.